AtriCure

AtriCure, Inc. engages in the development, manufacture, and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in Mason, OH.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference being held virtually. AtriCure's management is scheduled to present on Monday, January 11, 2021, at 10:00 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visi

AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Conference Dates: Tuesday, December 1 to Thursday December 3, 2020 A link to the fireside chat presentation will be available on the “Investors” section of the Company's website at https://ir.atric

AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2020 financial results. “We are pleased with our third quarter performance and the improving trajectory of our business, which reflect the commitment of our team and underlying demand in our core markets,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We are continuing to

AtriCure Reports Third Quarter 2020 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2020 to discuss its third quarter 2020 financial results. The call may be accessed through an operator by calling (844) 884-9951 for

AtriCure to Announce Third Quarter 2020 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference being held virtually.

AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021.

AtriCure Announces Angie Wirick as Chief Financial Officer

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2020 Results - Earnings Call Transcript

Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q2 results.

Recap: AtriCure Q2 Earnings

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results.

AtriCure Reports Second Quarter 2020 Financial Results

AtriCure, Inc. (ATRC) CEO Michael Carrel on Q1 2020 Results - Earnings Call Transcript

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2019 Results - Earnings Call Transcript

AtriCure has moved higher as of late, but there could definitely be trouble on the horizon for this company.

AtriCure Enters Overbought Territory

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2019 Results - Earnings Call Transcript

AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.

AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2019 Results - Earnings Call Transcript

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know

President, CEO, & Director of Atricure Inc (NASDAQ:ATRC) Michael H Carrel (insider trades) sold 25,000 shares of ATRC on 07/10/2019 at an average price of $32 a share.

Atricure Inc (ATRC) President, CEO, & Director Michael H Carrel Sold $800,000 of Shares

AtriCure's (ATRC) CEO Mike Carrel on Q1 2019 Results - Earnings Call Transcript

News for AtriCure Stock (ATRC)